Related references
Note: Only part of the references are listed.Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck
Fa-Yu Liu et al.
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY (2010)
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival
Sean M. McBride et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
David M. Peereboom et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J. Raizer et al.
NEURO-ONCOLOGY (2010)
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
W. K. Alfred Yung et al.
NEURO-ONCOLOGY (2010)
Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
N. Presneau et al.
BRITISH JOURNAL OF CANCER (2009)
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Douglas W. McMillin et al.
CANCER RESEARCH (2009)
Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Dexin Kong et al.
CURRENT MEDICINAL CHEMISTRY (2009)
PI3K and mTOR inhibitors - a new generation of targeted anticancer agents
Saskia Brachmann et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy
Hai-Yan Zhang et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2009)
Glioblastoma multiforme: a review of where we have been and where we are going
Cory Adamson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Genomic Aberrations in 80 Cases of Primary Glioblastoma Multiforme: Pathogenetic Heterogeneity and Putative Cytogenetic Pathways
Hanne-Sofie S. Dahlback et al.
GENES CHROMOSOMES & CANCER (2009)
Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Michael D. Prados et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Honokiol-mediated Inhibition of PI3K/mTOR Pathway A Potential Strategy to Overcome Immunoresistance in Glioma, Breast, and Prostate Carcinoma Without Impacting T Cell Function
Courtney Crane et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide
Tobias Sinnberg et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
Ta-Jen Liu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor
Changye Y. Zou et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair
M-A Westhoff et al.
ONCOGENE (2009)
Identification of survival-related genes of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma multiforme
Yolanda Ruano et al.
CANCER (2008)
Yes and PI3K bind CD95 to signal invasion of glioblastoma
Susanne Kleber et al.
CANCER CELL (2008)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling
Stephen E. Kendall et al.
STEM CELLS (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma
Qi-Wen Fan et al.
CANCER RESEARCH (2007)
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy
Eduard B. Dinca et al.
JOURNAL OF NEUROSURGERY (2007)
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan et al.
CANCER CELL (2006)
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response
JN Sarkaria et al.
CLINICAL CANCER RESEARCH (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
